Pfizer Vaccines President Mark Swindell On Prevenar 13 in Developing Countries And Emerging Markets: An Interview With PharmAsia News

Pfizer and GlaxoSmithKline attracted attention earlier this year while finalizing an agreement with the public-private GAVI Alliance to bring the newest pneumococcal vaccines - Prevenar 13 and Synflorix, respectively - to developing countries. Pfizer announced in August that the World Health Organization granted prequalification status to Prevenar 13, a condition for the drug to be used by United Nations agencies, including UNICEF. Pfizer Vaccines President Mark Swindell spoke with PharmAsia News following the WHO announcement to discuss the company's vaccine strategy in emerging markets.